Changes in Hong Kong stocks | Genting Xinyao (01952) rose nearly 6% intraday with EVM14 injection to launch phase I clinical trials intended to be suitable for treatment of squamous non-small cell lung cancer, etc.

The Zhitong Finance App learned that Genting Xinyao (01952) rose nearly 6% in the intraday period. As of press release, it had risen 5.86% to HK$40.12, with a turnover of HK$91.70,800.

According to the news, on January 4, according to data from the drug clinical trial registration and information disclosure platform, Genting Xinyao (Beijing) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Genting Xinyao, began a phase I study to evaluate the safety, tolerability, and initial efficacy of EVM14 monotherapy in selected patients with solid tumors.

The main purpose of this trial was to evaluate the safety and tolerability of EVM14 monotherapy in patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma, and to determine the RP2D of the treatment; the secondary purpose was to evaluate its antitumor activity. The exploratory aims include exploring the correlation between biomarker expression and efficacy, and evaluating immunogenicity, pharmacokinetics, and resistant antibodies.

EVM14 injection is a biological product intended for the treatment of patients with squamous non-small cell lung cancer and squamous cell carcinoma of the head and neck. Squamous non-small cell lung cancer is a common type of lung cancer. Symptoms include cough, hemoptysis, etc., which are diagnosed by imaging and pathology; head and neck squamous cell carcinoma mostly originates from mucous membranes and has symptoms such as ulcers and lumps, and can be diagnosed by pathological examination.